The CDTI Innovation attached 127 billion in subsidies to spanish companies adopted by the IPCEI Med4Cure Health of the european Union

The CDTI innovation, Enterprise Public Entity (E.P.E.) attached to the ministry of Science, innovation and universities, has published the final resolution to the financing of spanish companies participating in the Important Project of Common European Interest (IPCEI) Med4Cure, having approved the granting of subsidies in the total amount of 126,9 million euros. This action is part of spain to strengthen the resilience of the health sector, drive innovation sustainable and placing national companies in the forefront european research and pharmaceutical production.

The IPCEI Med4Cure, first initiative of its kind in the health field received the endorsement of the european commission in may 2024, with a view to addressing strategic challenges: from the development of advanced therapies for rare diseases and antimicrobial resistance until the adoption of production processes more sustainable and efficient.
Spain joined five member states — Belgium, france, Hungary, italy — to report the participation of 13 companies in 14 projects, which acts as a direct participant (Sylentis) and five as partners: Pharmaceutical Laboratories Rovi, S.A., laboratories Reig Jofre, S.A., Medichem, S.A., Minoryx Pharmaceuticals, S.L. and Oryzon Genomics, S.A.

AID

A boost to r + D + i and the industrial deployment

The line of direct aid published today funded r & D for six participants and also the first industrial deployment for the direct partner (Sylentis). In particular:

• SYLENTIS, S.A.:21.107.943 euros for the rehabilitation and GMP certification of its plant oligonucleótidos in Getafe, incorporating BREEAM standards and reducing the Process Mass Intensity (PMI), while moving in preclinical phase of new applicants for therapeutic purposes.
• PHARMACEUTICAL LABORATORIES ROVI, S.A.:36.341.035,65 euros for the project LAISOLID, focused on technology aseptic filling matrices for polymer liberators of drugs and biological products.
• JOFRE REIG LABORATORIES, S.A.:13.172.313,89 euros for the project, which integrates EMINTECH génicas therapies, and against CAR-T bacteriófagos amr and rare diseases.
• MEDICHEM, S.A.:16.213.766,03 euros, which optimizes FDF4EU manufacturing processes of APIs and formulations specializing in areas such as cystic fibrosis.
• MINORYX PHARMACEUTICALS, S.L.:26.876.530,85 euros for the LERI4CNS, which will validate the leriglitazona clinicamente for leucodistrofias and other rare diseases of the cns.
• ORYZON GENOMICS, S.A.:13.263.794,06 euros for VANDAM, custom epigenéticas therapies in disorders of tumours neuro-development clinic and rare.

In total, the eligible budget at the national level amounts to €224.636.453, CDTI Innovation covers 56 per cent through direct subsidy.

Impact and prospects

This call, funded by the mechanism for the recovery and resilience (MRR) and aligned with the LOSS of health of Vanguard, reflects the strategic vocation ministry of science, innovation and universities to support and build on the ecosystem biopharmaceutical english. Through CDTI Innovation, is achieved by:

1. Enhance the internationalization of spanish companies, facilitating their position in multinational companies.
2. Strengthening industrial capacities in critical technologies, such as oligonucleótidos cellular therapy, green production processes and bioinformatics.
3. Create skilled jobs and in attracting private investment, strengthening the competitiveness of Spain in the european research area.
4. Spread the knowledge and results — publications, RAND licensing, conferences — to ensure the generation of positive externalities (spillovers) throughout the eu.
5. Strengthening the CDTI branding innovation as the spanish agency for innovation, recognized by its ability to streamlined management, technical expertise and european vocation.

The implementation of these projects represents a qualitative leap in the value chain spanish and european pharmaceutical, and the creation of 6,000 estimated direct and indirect employment throughout the european Union. In addition, it was hoped that the return of knowledge will stimulate further research, new businesses and clusters of innovation, especially in the community of Madrid and other regions with high density of R & D.

The ministry of science, innovation and universities and CDTI Innovation maintain a commitment to promote and accompany companies during implementation, certification and disbursement of aid, ensuring compliance with the objectives and milestones set by the european commission for the recovery Plan, transformation and Resilience. This performance, spain reinforces its leading position in the Med4Cure IPCEI, contributing to the sovereignty, the transition of the pharmaceutical industry and well-being of citizens.

Full text of resolution available at:https :// www.cdti.es/sites/default/files/2025-07/ipcei _ health _ 2025 _ resolution _ final _ web.pdf

More information on the convening IPCEI Med4Cure Health:https :// www.cdti.es/aid/proyecto-importante-de-interes-comun-europeo-ipcei-de-salud-med4cure-0

CDTI Innovation

The centre for technological development and innovation, CDTI E.P.E. is a public company under the ministry of Science, innovation and universities, whose goal is the promotion of technological innovation in business. The CDTI mission is to ensure that the business fabric english generates and transform knowledge into growth científico-técnico globally competitive, sustainable and inclusive. By 2024, within the framework of a new strategic plan, the CDTI provided more than $2.3 billion euros of support for business startups and spain.

More information:

Office of the press
prensa@cdti.es
91-581.55.00

On The Internet
Website:www.cdti.es
In Linkedin:https :// www.linkedin.com/company/29815
X:https :// twitter.com/CDTI _ innovation
On Youtube:https :// www.youtube.com/user/CDTIoficial

This content is copyright © 2025 CDTI, Soes. Permitted for use and reproduction by quoting the source and digital identity of CDTI (@CDTI _ innovation).